ATL loses round in patent suit
Ultrasound vendor ATL of Bothell, WA, is planning to appeal adecision by the U.S. Court of Appeals for the Federal Districtthat upheld a lower court ruling that it infringed on a patentheld by SRI International of Palo Alto, CA. At issue is a circuitused
Ultrasound vendor ATL of Bothell, WA, is planning to appeal adecision by the U.S. Court of Appeals for the Federal Districtthat upheld a lower court ruling that it infringed on a patentheld by SRI International of Palo Alto, CA. At issue is a circuitused to track ultrasound signals in ATL's Ultramark 4 scanneras well as two discontinued products, Ultramark 5 and ADR 4000(SCAN 2/24/93). The patent expired in April 1994, and ATL saidthat due to the expiration there will be no impact on the company'sability to deliver products.
SRI filed a request for partial summary judgment on its claimin July 1991, and in November 1992 a U.S. district court judgeruled on that motion and determined that ATL had infringed SRI'spatent.
ATL appealed that ruling, but on Dec. 29 announced that theappeals court affirmed the lower court's ruling. ATL said it "willcontinue to seek legal remedies." SRI has claimed $5 millionin damages. A jury trial for the case is pending.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
